| Assay Method Information | |
| | Intein inhibitors as potential Tuberculosis drugs |
| Description: | Southern Research's Specialized Biocontainment Screening Center (SRSBSC) Southern Research Institute (Birmingham, Alabama) NIH Molecular Libraries Probe Production Centers Network (MLPCN) Assay Provider: Dr. Henry Paulus, Boston Biomedical Research Institute Award: 1 R03 MH087438-01 Tuberculosis (TB) is globally the most widespread infectious disease. Two billion people, one third of the world's population, are infected with Mycobacterium tuberculosis and 5-10% of these suffer active disease, leading to nearly 3 million deaths annually. The alarming world-wide increase in multidrug-resistant and extensively drug-resistant TB calls for new anti-mycobacterial drugs against new types of targets that are less likely to undergo mutations that lead to drug resistance. This project seeks to identify inhibitors of protein splicing, which is essential for the expression of three genes in M. tuberculosis. Protein splicing inhibitors, by disabling two separate vital functions and at th |
| Affinity data for this assay | |
|---|---|
| If you find an error in this entry please send us an E-mail | |